1.Relationship between pregnancy rate and serum progesterone concentration in cases of porcine embryo transfer.
Joonho MOON ; Ji Yei CHOI ; Jung Taek KANG ; Sol Ji PARK ; Su Jin KIM ; Goo JANG ; Byeong Chun LEE
Journal of Veterinary Science 2014;15(1):167-171
The level of P4 at the time of embryo transfer (ET) is important. P4 concentrations and numbers of corpora lutea for 126 recipients were evaluated. Nuclear transfer embryos were transferred into 126 surrogates. 11 maintained their pregnancy until full-term delivery, 17 miscarried, and implantation failed in 98 animals. P4 levels in the full-term group were significantly different from those of the pigs that aborted or in which implantation failed (p < 0.05). However, the numbers of corpora lutea were not significantly different. These findings indicate that the concentration of progesterone can be an important factor for successful ET in pigs.
Animals
;
Corpus Luteum/*physiology
;
Embryo Transfer/*veterinary
;
Embryo, Mammalian/*physiology
;
Female
;
Nuclear Transfer Techniques
;
Pregnancy
;
*Pregnancy Rate
;
Progesterone/*blood
;
Retrospective Studies
;
Sus scrofa/*physiology
2.Obstetrical Outcomes of Idiopathic Thrombocytopenic Purpura in Pregnancy.
Song Ah SONG ; Seung Ju SHIN ; Young Il CHOI ; Su Hyen KIM ; Ji Eun SHIN ; Yei Eun OH
Korean Journal of Perinatology 2007;18(4):378-384
OBJECTIVE: Idiopathic thrombocytopenic purpura (ITP) frequently occurs in young women. Consequently, clinicians often give medical treatment to pregnant women who are diagnosed with ITP. This study might help to make a clinical guidelines for obstetrical ITP patients and their infants. METHODS: We retrospectively investigated the medical charts of 19 cases of deliveries and 22 neonates which from mothers with the diagnosis of ITP during pregnancy from March 1998 to March 2007. RESULT: Corticosteroid treatment was administrated in 13 cases, high-dose immunoglobulin therapy in 3 cases, and concentrated platelet transfusion in 17 cases during their antenatal care. Ten (45%) vaginal deliveries and twelve (55%) cesarean sections were performed. There were no obstetrical complications associated with their ITP and only four infants with platelet counts below the 150,000/micronLiter were reported after birth. However there were not any signs and symptoms of neonatal complications resulting from their maternal ITP. CONCLUSION : Our results demonstrate that mothers with ITP can successfully deliver healthy infants in most case. Although maternal and fetal bleeding may occur, such a fatal complication is uncommon.
Blood Platelets
;
Cesarean Section
;
Diagnosis
;
Female
;
Hemorrhage
;
Humans
;
Immunization, Passive
;
Infant
;
Infant, Newborn
;
Mothers
;
Parturition
;
Platelet Count
;
Platelet Transfusion
;
Pregnancy*
;
Pregnant Women
;
Purpura, Thrombocytopenic, Idiopathic*
;
Retrospective Studies
3.Development of Dose Planning System for Brachytherapy with High Dose Rate Using Ir-192 Source.
Tae Jin CHOI ; Ji Won YEI ; Jin Hee KIM ; OK KIM ; Ho Joon LEE ; Hyun Soo HAN
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2002;20(3):283-293
PURPOSE: A PC based brachytherapy planning system was developed to display dose distributions on simulation images by 2D isodose curve including the dose profiles, dose-volume histogram and 3D dose distributions. MATERIALS AND METHODS: Brachytherapy dose planning software was developed especially for the Ir-192 source, which had been developed by KAERI as a substitute for the Co-60 source. The dose computation was achieved by searching for a pre-computed dose matrix which was tabulated as a function of radial and axial distance from a source. In the computation process, the effects of the tissue scattering correction factor and anisotropic dose distributions were included. The computed dose distributions were displayed in 2D film image including the profile dose, 3D isodose curves with wire frame forms and dose- volume histogram. RESULTS: The brachytherapy dose plan was initiated by obtaining source positions on the principal plane of the source axis. The dose distributions in tissue were computed on a 200x200 (mm2) plane on which the source axis was located at the center of the plane. The point doses along the longitudinal axis of the source were 4.5~9.0% smaller than those on the radial axis of the plane, due to the anisotropy created by the cylindrical shape of the source. When compared to manual calculation, the point doses showed 1~5% discrepancies from the benchmarking plan. The 2D dose distributions of different planes were matched to the same administered isodose level in order to analyze the shape of the optimized dose level. The accumulated dose-volume histogram, displayed as a function of the percentage volume of administered minimum dose level, was used to guide the volume analysis. CONCLUSION: This study evaluated the developed computerized dose planning system of brachytherapy. The dose distribution was displayed on the coronal, sagittal and axial planes with the dose histogram. The accumulated DVH and 3D dose distributions provided by the developed system may be useful tools for dose analysis in comparison with orthogonal dose planning.
Anisotropy
;
Axis, Cervical Vertebra
;
Benchmarking
;
Brachytherapy*
4.Effectiveness of Fentanyl Transdermal Patch (Fentanyl-TTS, Durogegic(R)) for Radiotherapy Induced Pain and Cancer Pain: Multi-center Trial.
Seong Soo SHIN ; Seung Jae HUH ; Eun Kyung CHOI ; Jong Hoon KIM ; Seung Do AHN ; Sang Wook LEE ; Yeun Sil KIM ; Kyu Chan LEE ; Chang Geol LEE ; John JK LOH ; Mison CHUN ; Young Teak OH ; Ok Bae KIM ; Jin Hee KIM ; Chul Yong KIM ; Dae Sik YANG ; Woo Yoon PARK ; Bo Kyoung KIM ; Heung Lae CHO ; Ki Jung AHN ; Jong Young LEE ; Seon Min YUN ; Yong Chan AHN ; Do Hoon LIM ; Won PARK ; Ki Moon KANG ; Hong Gyun WU ; Hyun Soo SHIN ; Seong Soon JANG ; Eun Seog KIM ; Byung Sik NA ; Woong Ki JUNG ; Sung Ja AHN ; Taek Keun NAM ; Yong Ho KIM ; MI Hee SONG ; Sang Mo YUN ; Chul Seung KAY ; Ji Won YEI ; Suk Won PARK ; Seon Woo KIM
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2006;24(4):263-271
PURPOSE: To evaluate the effectiveness and safety of fentanyl-TTS in the management of radiotherapy induced acute pain and cancer pain treated with radiotherapy. MATERIALS AND METHODS: Our study was open labelled prospective phase IV multi-center study. the study population included patients with more 4 numeric rating scale(NRS) score pain although managed with other analgesics or more than 6 NRS score pain without analgesics. Patients divided into two groups; patients with radiotherapy induced pain (Group A) and patients with cancer pain treated with radiotherapy (Group B). All patients received 25 ug/hr of fentanyl transdermal patch. Primary end point was pain relief; second end points were change in patient quality of life, a degree of satisfaction for patients and clinician, side effects. RESULTS: Between March 2005 and June 2005, 312 patients from 26 participating institutes were registered, but 249 patients completed this study. Total number of patients in each group was 185 in Group A, 64 in Group B. Mean age was 60 years and male to female ratio was 76:24. Severe pain NRS score at 2 weeks after the application of fentanyl was decreased from 7.03 to 4.01, p=0.003. There was a significant improvement in insomnia, social functioning, and quality of life. A degree of satisfaction for patients and clinician was very high. The most common reasons of patients' satisfactions was good pain control. Ninety six patients reported side effect. Nausea was the most common side effect. There was no serious side effect. CONCLUSION: Fentanyl-TTS was effective in both relieving pain with good tolerability and improving the quality of life for patients with radiotherapy induced acute pain and cancer pain treated with radiotherapy. The satisfaction of the patients and doctors was good. There was no major side effect.
Academies and Institutes
;
Acute Pain
;
Analgesics
;
Female
;
Fentanyl*
;
Humans
;
Male
;
Nausea
;
Prospective Studies
;
Quality of Life
;
Radiotherapy*
;
Sleep Initiation and Maintenance Disorders
;
Transdermal Patch*